Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3846247 | 0.86 | SMN1; SMN2 (0.47) | KCNH2SMN1; SMN2NPC1RAB9AGRIN2B | |
| SCHEMBL13167704 | 0.80 | KCNH2 (0.60) | KCNH2MEN1KMT2A | |
| SCHEMBL11999873 | 0.80 | KCNH2 (0.52) | KCNH2 | |
| Hydrochloric Acid SCHEMBL3517676 | 0.79 | KCNH2 (0.59) | KCNH2MEN1KMT2A | |
| SCHEMBL13145833 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ACYP2C19ENPP2 | |
| SCHEMBL4144862 | 0.79 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL2797603 | 0.77 | KCNH2 (0.50) | KCNH2 | |
| SCHEMBL5747485 | 0.77 | HSD11B1 (0.45) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL12090574 | 0.76 | KCNH2 (0.48) | KCNH2 | |
| SCHEMBL10313867 | 0.75 | USP30 (0.48) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578743-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-11-29 | — | — | EP | disclosed |
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1578743-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004058144-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | KCNH2 3365/4885SMN1; SMN2 2706/4885NPC1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.